التفاصيل البيبلوغرافية
| العنوان: |
PARP-inhibitors in epithelial ovarian cancer: Actual positioning and future expectations. |
| المؤلفون: |
Vanacker, Hélène, Harter, Philipp, Labidi-Galy, Sana Intidhar, Banerjee, Susana, Oaknin, Ana, Lorusso, Domenica, Ray-Coquard, Isabelle |
| المصدر: |
Cancer Treatment Reviews; Sep2021, Vol. 99, pN.PAG-N.PAG, 1p |
| مستخلص: |
Poly-(ADP)-ribose polymerase inhibitors (PARPi) are a class of oral anticancer drugs first developed as "synthetically lethal" in cancers harboring BRCA1/BRCA2 inactivating mutations. In high-grade serous or endometrioid ovarian cancers (HGOC), PARPi demonstrated benefit as maintenance therapy in relapsing BRCA-mutated and non-mutated tumors. Recently, they extended their indications to frontline maintenance therapy. This review summarizes the current place of PARPi (i) as maintenance or single agent in recurrent disease and (ii) frontline maintenance with different settings. We reviewed the course of biomarker identification, the challenge of overcoming resistance to PARPi and future combinations with targeted therapies, including anti-angiogenic, immune checkpoint inhibitors and DNA damage response inhibitors. [ABSTRACT FROM AUTHOR] |
|
Copyright of Cancer Treatment Reviews is the property of W B Saunders and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Supplemental Index |
